VitaPath gets $6M to fight spina bifida
VitaPath Genetics, developer of a diagnostic that could be used to lessen rates of the birth defect spina bifida, has raised $6 million in a first round of funding led by Mohr Davidow Ventures. The money should provide the Foster City, Calif. with runway through next year, covering testing for women with a high chance of having a baby with spina bifida.
The condition, which causes a underdeveloped spinal column often leading to nerve and brain damage, occurs in eight babies born every day. VitaPath’s mission is to identify women at high risk for the defect before they even conceive. Those who are can potentially fix the problem by taking high amounts of folic acid.
X/Seed Capital Management also participated in the financing. It previously provided see money which was rolled into the round.
Next Story: Madison Dearborn buys majority stake in NextG Networks
Previous Story: Collecta releases API to spur development of real-time search apps
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.